What is the average price target for PALISADE BIO INC (PALI) stock?
14 analysts have analysed PALI and the average price target is 11.6 USD. This implies a price increase of 395.83% is expected in the next year compared to the current price of 2.34.
PALISADE BIO INC (PALI) Forecast, Price Target & Analyst Ratings
NASDAQ:PALI • US6963894026
Current stock price
2.34 USD
-0.46 (-16.43%)
At close:
2.37 USD
+0.03 (+1.28%)
Pre-Market:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PALISADE BIO INC (PALI).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.04
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$11.60
Upside
+ 395.83%
From current price of $2.34 to mean target of $11.60, Based on 14 analyst forecasts
Low
$5.05
Median
$7.65
High
$26.25
Price Target Revisions
1 Month
-13.61%
3 Months
-13.61%
Price Target Summary
14 Wall Street analysts provided a forecast for the next 12 months for PALI. The average price target is 11.6 USD. This implies a price increase of 395.83% is expected in the next year compared to the current price of 2.34.
The average price target has been revised downward by 13.61% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.29%
PALI was analyzed by 14 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about PALI.
In the previous month the buy percentage consensus was at a similar level.
PALI was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-09 | Wolfe Research | Initiate | Outperform |
| 2026-03-26 | HC Wainwright & Co. | Initiate | Buy |
| 2026-02-25 | Stifel | Initiate | Buy |
| 2026-01-09 | B. Riley Securities | Initiate | Buy |
| 2025-12-30 | Clear Street | Initiate | Buy |
| 2025-12-29 | Piper Sandler | Initiate | Overweight |
| 2025-05-13 | Brookline Capital | Maintains | Buy -> Buy |
| 2024-11-20 | Brookline Capital | Initiate | Buy |
| 2024-11-13 | Maxim Group | Maintains | Buy -> Buy |
| 2024-05-01 | Maxim Group | Reiterate | Buy -> Buy |
| 2024-04-16 | Maxim Group | Maintains | Buy -> Buy |
| 2023-11-17 | Maxim Group | Upgrade | Hold -> Buy |
| 2023-05-16 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2023-03-30 | Maxim Group | Upgrade | Hold -> Buy |
| 2022-08-19 | Maxim Group | Downgrade | Buy -> Hold |
| 2022-02-02 | Ladenburg Thalmann | Initiate | Buy |
| 2021-08-31 | Maxim Group | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.04
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 91.78%
- Number of Analysts
- 9
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
PALI is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -0.04 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | -100.00% | 250K | -100.00% | 61.989M | 84.727M 36.68% | 344.76M 306.91% | 61.059M -82.29% | 167.62M 174.52% | 442.98M 164.28% | |||||
| EBITDA YoY % growth | -11.735M -10.88% | -15.308M -30.45% | -12.841M 16.12% | N/A -15.69% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -11.737M -9.94% | -15.311M -30.45% | -12.845M 16.11% | -15.642M -15.68% | -12.11M 18.50% | -41.232M -240.47% | -55.764M -35.25% | -82.918M -48.69% | -77.883M 6.07% | -23.561M 69.75% | -40.445M -71.66% | 45.415M 212.29% | 277.62M 511.30% | |
| Operating Margin | N/A | N/A | -5,138.00% | N/A | N/A | N/A | N/A | -133.76% | -91.92% | -6.83% | -66.24% | 27.09% | 62.67% | |
| EPS YoY % growth | N/A | -247.95 91.73% | -29.10 88.26% | -11.90 59.53% | -0.78 87.18% | -0.23 85.08% | -0.28 -26.20% | -0.41 -44.22% | -0.31 24.13% | -0.04 86.07% | 0.10 323.53% | 0.52 431.58% | 1.76 241.58% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.04 91.78% | -0.05 91.76% | -0.06 83.40% | -0.08 -3.82% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -7.683M -232.61% | -9.033M -217.72% | -12.238M -274.07% | -15.378M -293.87% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
20.01%
EPS Next 5 Year
14.54%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
PALISADE BIO INC / PALI Forecast FAQ
When does PALISADE BIO INC (PALI) report earnings?
PALISADE BIO INC (PALI) will report earnings on 2026-05-11.
Can you provide the consensus estimates for PALISADE BIO INC next earnings?
The consensus EPS estimate for the next earnings of PALISADE BIO INC (PALI) is -0.04 USD and the consensus revenue estimate is 0 USD.